These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34273443)

  • 41. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Viola D; Elisei R; Bendlova B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Tufano RP; Pai SI; Zeiger MA; Westra WH; Clark DP; Clifton-Bligh R; Sidransky D; Ladenson PW; Sykorova V
    JAMA; 2013 Apr; 309(14):1493-501. PubMed ID: 23571588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis with ARMS PCR.
    Zhang J; Yang Y; Zhao J; Shi L; Xu Y; Yu K; Guo C
    Pathol Res Pract; 2019 Apr; 215(4):761-765. PubMed ID: 30819583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular characterization of tumors meeting diagnostic criteria for the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
    Pool C; Walter V; Bann D; Goldenberg D; Broach J; Hennessy M; Cottrill E; Washburn E; Williams N; Crist H; Imamura Y; Warrick JI
    Virchows Arch; 2019 Mar; 474(3):341-351. PubMed ID: 30645670
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China.
    Huang M; Yan C; Xiao J; Wang T; Ling R
    Diagn Pathol; 2019 Jul; 14(1):74. PubMed ID: 31300059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
    Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Downregulation of SMOC2 expression in papillary thyroid carcinoma and its prognostic significance.
    Kim HS; Choi JH; Lee JY; Kang J; Myung JK; Kim WH; Jang BG
    Sci Rep; 2020 Mar; 10(1):4853. PubMed ID: 32184420
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The downregulation of lncRNA EMX2OS might independently predict shorter recurrence-free survival of classical papillary thyroid cancer.
    Gu Y; Feng C; Liu T; Zhang B; Yang L
    PLoS One; 2018; 13(12):e0209338. PubMed ID: 30576338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.
    Rusinek D; Swierniak M; Chmielik E; Kowal M; Kowalska M; Cyplinska R; Czarniecka A; Piglowski W; Korfanty J; Chekan M; Krajewska J; Szpak-Ulczok S; Jarzab M; Widlak W; Jarzab B
    PLoS One; 2015; 10(12):e0143688. PubMed ID: 26625260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.
    Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Strupas K
    Langenbecks Arch Surg; 2017 Mar; 402(2):227-234. PubMed ID: 28160058
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer.
    Kim SJ; Lee KE; Myong JP; Park JH; Jeon YK; Min HS; Park SY; Jung KC; Koo do H; Youn YK
    World J Surg; 2012 Feb; 36(2):310-7. PubMed ID: 22190222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of key genes of papillary thyroid carcinoma by integrated bioinformatics analysis.
    Xue G; Lin X; Wu JF; Pei D; Wang DM; Zhang J; Zhang WJ
    Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32766727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells.
    Lee G; Kang YE; Oh C; Liu L; Jin Y; Lim MA; Won HR; Chang JW; Koo BS
    Auris Nasus Larynx; 2020 Oct; 47(5):870-880. PubMed ID: 32381353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular analyses of thyroid tumors for diagnosis of malignancy on fine-needle aspiration biopsies and for prognosis of invasiveness on surgical specimens.
    Rousset B; Ziercher L; Borson-Chazot F
    Ann Endocrinol (Paris); 2011 Apr; 72(2):125-8. PubMed ID: 21511245
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
    Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
    World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.
    Zhao L; Zhu XY; Jiang R; Xu M; Wang N; Chen GG; Liu ZM
    Int J Clin Exp Pathol; 2015; 8(9):11236-47. PubMed ID: 26617848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. EZH2 upregulation by ERα induces proliferation and migration of papillary thyroid carcinoma.
    Xue L; Yan H; Chen Y; Zhang Q; Xie X; Ding X; Wang X; Qian Z; Xiao F; Song Z; Wu Y; Peng Y; Xu H
    BMC Cancer; 2019 Nov; 19(1):1094. PubMed ID: 31718595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Surgery; 2015 Dec; 158(6):1500-11. PubMed ID: 26120069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.